Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGEN Agenus	$4.80 +0.8%	$5.42	$1.38 ▼ $7.34	$131.60M	1.62	1.11 million shs	605,793 shs
LXRX Lexicon Pharmaceuticals	$1.08 -3.6%	$0.94	$0.28 ▼ $2.18	$390.41M	1.17	3.27 million shs	2.81 million shs
MYGN Myriad Genetics	$6.32 +3.6%	$5.00	$3.76 ▼ $29.30	$588.04M	1.89	2.31 million shs	2.41 million shs
RIGL Rigel Pharmaceuticals	$31.70 +4.1%	$20.59	$9.92 ▼ $32.40	$568.60M	1.21	376,274 shs	1.37 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGEN Agenus	0.00%	-10.45%	-18.92%	+63.82%	-5.51%
LXRX Lexicon Pharmaceuticals	0.00%	+0.93%	-4.42%	+54.07%	-30.77%
MYGN Myriad Genetics	0.00%	+61.64%	+14.91%	+62.47%	-76.28%
RIGL Rigel Pharmaceuticals	0.00%	+44.68%	+61.73%	+68.53%	+221.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGEN Agenus	4.2001 of 5 stars	3.3	4.0	4.6	1.9	1.7	0.6
LXRX Lexicon Pharmaceuticals	2.7345 of 5 stars	3.3	3.0	0.0	2.5	2.5	0.6
MYGN Myriad Genetics	3.6114 of 5 stars	3.1	2.0	4.1	2.8	1.7	0.0
RIGL Rigel Pharmaceuticals	2.5168 of 5 stars	2.2	0.0	0.0	3.7	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGEN Agenus	2.67	Moderate Buy	$16.33	240.28% Upside
LXRX Lexicon Pharmaceuticals	2.50	Moderate Buy	$3.23	198.61% Upside
MYGN Myriad Genetics	2.21	Hold	$12.45	97.07% Upside
RIGL Rigel Pharmaceuticals	2.40	Hold	$38.20	20.50% Upside

Current Analyst Ratings Breakdown

Latest AGEN, RIGL, LXRX, and MYGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	LXRX Lexicon Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1.20 ➝ $1.90
8/6/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $32.00
6/24/2025	LXRX Lexicon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/4/2025	AGEN Agenus	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$4.00 ➝ $6.00
6/4/2025	AGEN Agenus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$25.00
5/21/2025	MYGN Myriad Genetics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$20.00 ➝ $6.00
5/15/2025	MYGN Myriad Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.50 ➝ $9.00
5/13/2025	AGEN Agenus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
5/13/2025	AGEN Agenus	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$3.00 ➝ $4.00

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGEN Agenus	$103.46M	1.27	N/A	N/A	($13.06) per share	-0.37
LXRX Lexicon Pharmaceuticals	$31.08M	12.56	N/A	N/A	$0.36 per share	3.00
MYGN Myriad Genetics	$837.60M	0.70	$1.00 per share	6.33	$4.17 per share	1.52
RIGL Rigel Pharmaceuticals	$179.28M	3.17	$1.08 per share	29.38	$4.57 per share	6.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGEN Agenus	-$227.21M	-$8.67	N/A	N/A	N/A	-196.12%	N/A	-82.33%	8/11/2025 (Estimated)
LXRX Lexicon Pharmaceuticals	-$200.40M	-$0.33	N/A	N/A	N/A	-206.43%	-83.63%	-42.22%	N/A
MYGN Myriad Genetics	-$127.30M	-$4.28	N/A	N/A	N/A	-47.45%	-5.17%	-3.44%	N/A
RIGL Rigel Pharmaceuticals	$17.49M	$5.41	5.86	30.19	N/A	36.51%	438.89%	57.03%	N/A

Latest AGEN, RIGL, LXRX, and MYGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	AGEN Agenus	-$0.78	N/A	N/A	N/A	$49.71 million	N/A
8/6/2025	Q2 2025	LXRX Lexicon Pharmaceuticals	-$0.08	$0.01	+$0.09	$0.01	$4.87 million	$28.87 million
8/5/2025	Q2 2025	RIGL Rigel Pharmaceuticals	$1.97	$3.28	+$1.31	$3.28	$64.58 million	$101.69 million
5/13/2025	Q1 2025	LXRX Lexicon Pharmaceuticals	-$0.10	-$0.07	+$0.03	-$0.07	$1.26 million	$1.26 million
5/12/2025	Q1 2025	AGEN Agenus	-$1.61	-$1.03	+$0.58	-$1.03	$26.38 million	$24.07 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGEN Agenus	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGEN Agenus	N/A	0.11	0.11
LXRX Lexicon Pharmaceuticals	0.43	4.16	2.22
MYGN Myriad Genetics	N/A	1.42	1.71
RIGL Rigel Pharmaceuticals	0.46	2.02	2.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGEN Agenus	61.46%
LXRX Lexicon Pharmaceuticals	74.70%
MYGN Myriad Genetics	99.02%
RIGL Rigel Pharmaceuticals	66.23%

Insider Ownership

Company	Insider Ownership
AGEN Agenus	5.50%
LXRX Lexicon Pharmaceuticals	13.90%
MYGN Myriad Genetics	2.40%
RIGL Rigel Pharmaceuticals	9.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGEN Agenus	440	27.42 million	25.91 million	Optionable
LXRX Lexicon Pharmaceuticals	140	361.49 million	311.25 million	Optionable
MYGN Myriad Genetics	2,700	93.04 million	90.81 million	Optionable
RIGL Rigel Pharmaceuticals	160	17.94 million	16.24 million	Optionable

AGEN, RIGL, LXRX, and MYGN Headlines

Recent News About These Companies

RIGL FY2025 EPS Forecast Increased by Cantor Fitzgerald

August 9 at 9:28 AM | marketbeat.com

HC Wainwright Issues Optimistic Estimate for RIGL Earnings

August 9 at 8:09 AM | marketbeat.com

HC Wainwright Issues Positive Estimate for RIGL Earnings

August 9 at 2:57 AM | americanbankingnews.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Reaches New 1-Year High on Analyst Upgrade

August 9 at 2:19 AM | americanbankingnews.com

Earnings Estimates Moving Higher for Rigel (RIGL): Time to Buy?

August 8 at 1:20 PM | zacks.com

Best Momentum Stock to Buy for August 8th

August 8 at 11:01 AM | zacks.com

Results: Rigel Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

August 8 at 10:18 AM | finance.yahoo.com

5 Best Stocks With Relative Price Strength to Buy Right Now

August 8 at 10:15 AM | zacks.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Hits New 1-Year High Following Analyst Upgrade

August 8 at 7:48 AM | marketbeat.com

New Strong Buy Stocks for August 8th

August 8 at 7:10 AM | zacks.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Up on Earnings Beat

August 8 at 2:45 AM | americanbankingnews.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q2 2025 Earnings Call Transcript

August 7 at 12:13 PM | msn.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

August 7 at 10:56 AM | marketbeat.com

Rigel Pharmaceuticals (RIGL) Just Flashed Golden Cross Signal: Do You Buy?

August 7 at 10:55 AM | zacks.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Up After Strong Earnings

August 7 at 10:32 AM | marketbeat.com

Rigel Pharmaceuticals, Inc. (RIGL) Hits Fresh High: Is There Still Room to Run?

August 7 at 10:16 AM | zacks.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Announces Earnings Results

August 6, 2025 | marketbeat.com

Rigel (RIGL) Q2 Revenue Jumps 176%

August 6, 2025 | theglobeandmail.com

Rigel Pharmaceuticals Inc (RIGL) Q2 2025 Earnings Report Preview: What To Look For

August 6, 2025 | finance.yahoo.com

Rigel Pharmaceuticals Inc (RIGL) Q2 2025 Earnings Call Highlights: Record Revenue and Raised ...

August 6, 2025 | gurufocus.com

Rigel Pharmaceuticals reports Q2 EPS $3.91, consensus $1.40

August 6, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
Why the American Eagle Stock Rally Isn't Just Speculation
By Gabriel Osorio-Mazilli | July 28, 2025
View Why the American Eagle Stock Rally Isn't Just Speculation
This Drone Stock Is on Sale Despite Big Army Contract
By Jeffrey Neal Johnson | July 31, 2025
View This Drone Stock Is on Sale Despite Big Army Contract
America Wants Drone Dominance: Are These Stocks Ready to Soar?
By Chris Markoch | July 20, 2025
View America Wants Drone Dominance: Are These Stocks Ready to Soar?
ServiceNow: The 2nd Wave of AI Spending Is Here
By Thomas Hughes | July 25, 2025
View ServiceNow: The 2nd Wave of AI Spending Is Here

AGEN, RIGL, LXRX, and MYGN Company Descriptions

Agenus NASDAQ:AGEN

$4.80 +0.04 (+0.84%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$4.80 +0.00 (+0.10%)

As of 08/8/2025 07:56 PM Eastern

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Lexicon Pharmaceuticals NASDAQ:LXRX

$1.08 -0.04 (-3.57%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$1.09 +0.01 (+0.93%)

As of 08/8/2025 07:59 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Myriad Genetics NASDAQ:MYGN

$6.32 +0.22 (+3.61%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$6.33 +0.01 (+0.16%)

As of 08/8/2025 07:51 PM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Rigel Pharmaceuticals NASDAQ:RIGL

$31.70 +1.26 (+4.14%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$31.66 -0.04 (-0.14%)

As of 08/8/2025 07:59 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time